Lancet commission flags unequal access to genomic cancer testing
- A new Lancet Oncology commission found unequal access to cancer genetic testing and treatment worldwide.
- About half of the 3.14 lakh women eligible yearly for BReast CAncer gene BRCA testing do not get it, mostly in poorer countries.
- Only 2% of biomarker-based cancer trials are held in low- and middle-income countries, against 81% in richer ones.
- Global cancer drug spending rose 75% in five years to $252 billion in 2024, and may reach $441 billion by 2029.
Source: ndtv.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
